No bashing here. I'd love to be selling some shares at $5 after a deal is announced tomorrow. I simply had some questions about BTD and whether the small sample size is a threat to it or even our EOP2 meeting. It seems like B-OM is a slam dunk based on the data IPIX has released.

The only possible chink in the armor is the small number of patients. Legitimate questions. Looking for someone with real answers rather than accusations of bashing.

Go IPIX!